Research Assistant Appreciation

Please join us in giving a special shoutout to one of our research assistants on the Ark Clinical Research team, Ira! We are so appreciative and proud of your hard work and gentle care you provide for our patients!  Thank you, Ira!

Ira Yelp Review


New RSV Vaccine FDA Approved

A new RSV Vaccine has been approved by the FDA to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. 

Ark Clinical Research is thrilled to have contributed to this wonderful achievement!


Advancing Accessibility for Obesity

Ark Clinical Research announces advancing accessibility for obesity through innovative research trials on GLP-1 drugs.


Introducing our PBMC Lab Specialists

Ark Clinical Research proudly presents our PBMC Lab Specialists, Amee Marin and Angelica Soto!  We hear from our Sponsors repeatedly about the high volume and excellent quality they produce as opposed to other sites! We are so honored and grateful to have these wonderful team members as part of our organization. Great job, Amee and Angelica!!!

PBMC Lab specialists

Fountain Valley Open House


Ark Clinical Research had a wonderful time hosting an Open House in celebration of our new Fountain Valley office! Thank you to everyone who joined us! It was such a great pleasure seeing familiar faces again and connecting with the new neighboring doctors and healthcare workers in our community. The event was very meaningful for us as it marks one of many milestones for our company’s growth. We’ll strive to work even harder to improve each patient’s quality of life through the development of more effective therapies and devices by conducting high quality clinical trials.

Pfizer RSV Vaccine


Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO(R) for RSV in Older Adults. Ark Clinical Research is proud to share our important contribution to getting this important vaccine approved!


We're excited to announce the newest addition to the Ark team, Kellee Kim!

Kellee joins Ark Clinical Research as the Director of Business Development! Kellee brings her impressive background in real estate, healthcare, and biotech to the Ark team.  Her past work experiences include Vice President of Healthcare & Life Science at LPC West where she led acquisitions and developed a successful life science strategy for the company.  With a Wharton MBA and an extensive history of driving significant deals, she brings her expertise and experience to our organization.

Welcome Kellee!


Exciting Leadership Announcement at Ark Clinical Research


We are thrilled to announce that Samira Moran, who joined us as President in February 2023, has been appointed as our new Chief Executive Officer effective February 5, 2024… Since her arrival, Samira has proven herself as a seasoned executive, bringing innovation and strategic vision to our team. With her leadership, Ark has opened up a new clinical trial site on the Fountain Valley medical campus, expanded Ark’s vaccine and COVID therapeutic areas, and added metabolic (diabetes, obesity, hyperlipidemia, NASH) therapeutic areas, where Ark is already the leading enrolling site in many studies. Her dedicated focus on growth and therapeutic expansion has played a crucial role in our success. We are genuinely grateful to have Samira leading us into the future. Dr. Kenneth Kim will step into the role of Executive Chairman of Ark Clinical Research and remain a PI for allergy studies in Long Beach and for metabolic studies in Fountain Valley. We are excited about the journey ahead and the continued success of Ark under Samira’s leadership!

Samira Moran

Happy Holidays from the Ark Team!


Happy Holidays from Ark Clinical Research! We’ve had a great year filled with accomplishments and challenges. Ark Clinical Research has experienced research growth in the areas of Vaccines, Metabolic and Liver Disease among many other indications. We have a new site open in Fountain Valley, a community based in Orange County, which is based on a hospital campus. We are super excited to have you visit! We are truly grateful for our patients, Sponsors, and vendors. We appreciate you and look forward to an exciting 2024!!

Holiday Greeting

Winter Wonderland Toy Drive 2023


Ark Clinical Research was super excited to see everyone at the Winter Wonderland Toy Drive! It was an eventful day filled with fun activities, music, and giveaways! We hope that the free blood sugar testing we provided at least contributed to your health and that you learned about our clinical trials within the community.

Toy Drive 3
Toy Drive 1
Toy Drive 4

Special Health Event


Ark Clinical Research hosted a special health event in collaboration with one of our key sponsors! Through the sponsor’s mobile research unit, pre-screenings were offered to see which patients qualified for two of our type 2 diabetes studies as well as an Ark information booth stationed to provide additional details on our other clinical studies in areas of COVID-19, healthy volunteers, allergy, and metabolic diseases especially to those who did not qualify for the pre-screening.

Eli Lilly Mobile Event 1
Eli Lilly Mobile Event 2
eli lilly mobile event 3



Covid-19 Drug Prevents Symptomatic Disease in Study, Regeneron Says An antibody drug from Regeneron Pharmaceuticals Inc. reduced the risk of developing symptomatic Covid-19 infection by 81% compared with a placebo in people living with someone infected by the new coronavirus, a study found.



Vaccine trial participant and CNN correspondent’s big reveal. Was it the placebo or the real thing?  Ark Clinical unblinds CNN reporter participating in the Johnson vaccine trial.

Antibody Cocktail


PHASE 3 TRIAL SHOWS REGEN-COV™ (CASIRIVIMAB WITH IMDEVIMAB) ANTIBODY COCKTAIL REDUCED HOSPITALIZATION OR DEATH BY 70% IN NON-HOSPITALIZED COVID-19 PATIENTS.  Ark is performing these studies and after enrolling hundreds of patients , we can attest to the power of these treatments in preventing severe disease.

Johnson & Johnson


Johnson & Johnson’s single-dose vaccine provides strong shield against severe COVID Johnson & Johnson’s one-shot vaccine generated strong protection against Covid-19 in a large, late-stage trial, raising hopes that it can rapidly reshape a stumbling immunization campaign.

Read in Bloomberg:



Because of excellent data with the Regeneron monoclonal antibody study, the 2067 protocol will now be eliminating the placebo arm.

Masks Forever?


Will We Have to Wear Masks Forever? Innovation Advisor Dr. Kenneth Kim Weighs in on the COVID-19 Vaccines.

Latino Community


Dr. Kim shares his thoughts on a ABC vaccine panel on reaching the Latino community this past week.

Single Shot


Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial.



REGENERON REPORTS POSITIVE INTERIM DATA WITH REGEN-COV™ ANTIBODY COCKTAIL USED AS PASSIVE VACCINE TO PREVENT COVID-19.  We have been running this trial for the last several months at Ark Clinical Research, and it is nothing short of amazing results.  We have not seen anyone get sick who entered the trial get sick, and this report shows 100% prevention of symptomatic infection among family who took the drug!

Vaccination Rates


Analysis: My Covid-19 vaccine trial experience remains vital as vaccination rates are lagging.

Interim Phrase


Johnson & Johnson COVID-19 Vaccine Candidate Interim Phase 1/2a Data Published in New England Journal of Medicine.

Neutralizing Antibody


Lilly’s neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents.

Covid-19 Vaccine


What’s Happening With Johnson & Johnson’s Covid-19 Vaccine?

FDA Emergency Authorization


CNN article on the Regeneron COVID Treatment Studies – Regeneron asks FDA for emergency authorization of its Covid-19 antibody therapy given to Trump last week.



Dr. Kim’s appearance on Univision – ¿Qué efectividad puede tener el cóctel experimental de medicamentos que le están suministrado a Trump?

Reduced Viral Levels


Regeneron’s REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients.



Fauci on ‘Highly Specific, Direct’ Therapy for COVID-19.